Deciphera Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Deciphera Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials 6 currently recruiting 6 completed early-phase tilt top decile by trial count

Deciphera Pharmaceuticals: 21 sponsored US clinical trials, 6 recruiting.

Deciphera Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tenosynovial Giant Cell Tumor, with 3 trials.

Top-decile sponsor footprint

Deciphera Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 1

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
RECRUITING

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

NCT07075471
RECRUITING Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NCT06966024
RECRUITING Phase 1

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

NCT06630234
RECRUITING Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
RECRUITING Phase 1

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367
ACTIVE NOT RECRUITING Phase 3

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105
ACTIVE NOT RECRUITING Phase 3

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
ACTIVE NOT RECRUITING Phase 1

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

NCT04892017
ACTIVE NOT RECRUITING Phase 3

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501
ACTIVE NOT RECRUITING Phase 1

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469
COMPLETED Phase 1

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411
COMPLETED Phase 1

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

NCT07158398
TERMINATED Phase 1

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463
COMPLETED Phase 1

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

NCT04530981
TERMINATED Phase 1

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415
TERMINATED Phase 1

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

NCT03601897
COMPLETED Phase 3

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

NCT03353753
COMPLETED Phase 1

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

NCT02571036
TERMINATED Phase 1

A Study of DCC-2701 in Participants With Advanced Solid Tumors

NCT02228811
COMPLETED Phase 1

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

NCT00827138

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 1
Phase 3 4

Therapeutic Areas

Tenosynovial Giant Cell Tumor 3
Tenosynovial Giant Cell Tumor, Diffuse 2
Giant Cell Tumor of Tendon Sheath 2
Pigmented Villonodular Synovitis 2
GIST 2
GIST - Gastrointestinal Stromal Tumor 1
Tenosynovial Giant Cell Tumor, Localized 1
Advanced Malignant Neoplasm 1
Castration-resistant Prostate Cancer 1
Chronic Graft-versus-host Disease (cGVHD) 1

What is open in the Deciphera Pharmaceuticals pipeline

6 recruiting of 21 indexed (29% open); 6 completed (29%).

Phase mix: 4 late (III/IV) vs 16 early (I/II) (early-phase heavy).

Top condition: Tenosynovial Giant Cell Tumor (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Deciphera Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 21 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Deciphera PharmaceuticalsAEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of Pfizer89bioAlabama Physical Therapy & AcupunctureAlloSourceAlnylam Pharmaceuticals
Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Deciphera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Deciphera Pharmaceuticals page

21 registered trials is a research-attention snapshot, not an endorsement of Deciphera Pharmaceuticals or any single study.

  • 6 of Deciphera Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tenosynovial Giant Cell Tumor is the condition Deciphera Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tenosynovial Giant Cell Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Deciphera Pharmaceuticals pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.